Oliveira Jenny Lourdes Rivas de, Santos Magaly Arrais Dos, Arnoni Renato Tambellini, Ramos Auristela, Togna Dorival Della, Ghorayeb Samira Kaissar, Kroll Roberto Tadeu Magro, Souza Luiz Carlos Bento de
Instituto Dante Pazzanese de Cardiologia, São Paulo, SP, Brazil.
Braz J Cardiovasc Surg. 2018 Jan-Feb;33(1):32-39. doi: 10.21470/1678-9741-2017-0132.
Active infective endocarditis is associated with high morbidity and mortality. Surgery is indicated in high-risk conditions, and the main determinants of mortality in surgical treatment should be evaluated.
To identify mortality predictors in the surgical treatment of active infective endocarditis in a long-term follow-up.
This prospective observational study involved 88 consecutive patients diagnosed with active infective endocarditis, who underwent surgery between January 2005 and December 2015. Fifty-eight (65.9%) patients were male, the mean age was 50.87±16.15 years. A total of 31 (35.2%) patients had a history of rheumatic fever; 48 (54.5%) had had heart surgery with prosthetic valve implantation; 45 (93.8%) had biological prosthetic valve endocarditis and 3 (6.3%) mechanical prosthetic valve; 40 (45.5%) patients had the disease in their native valve. The mean EuroSCORE II was 8.9±6.5%, and the main surgical indication was refractory heart failure in 38 (43.2%) patients. A total of 68 bioprosthesis (36 aortic, 32 mitral) and 29 mechanical prostheses (12 aortic, 17 mitral) were implanted and three mitral valve plasties performed. A total of 25 (28.4%) patients underwent double or triple valve procedures. Aortic annulus reconstruction by abscess was performed in 18 (20.5%) and six (6.81%) patients had combined procedure. The mean surgery time was 359±97.6 minutes.
The overall survival in up to a 10-year follow-up period was 79.5%. In the univariate analysis, the main mortality predictors were positive blood cultures (P=0.003), presence of typical microorganisms (P=0.008), most frequently Streptococcus viridans (12 cases; 25%); C-reactive protein (hazard ratio [HR] 1.034, 95% confidence interval [CI] 1.000 to 1.070, P=0.04); creatinine clearance (HR 0.977, 95% CI 0.962 to 0.993, P=0.005); length of surgery: every five minutes multiplies the chance of death 1.005-fold (HR 1.005, 95% CI 1.001 to 1.009, P=0.0307); age (HR 1.060, 95% CI 1.026 to 1.096, P=0.001); and EuroSCORE II (HR 1.089, 95% CI 1.030 to 1.151, P=0.003).
A positive blood culture with typical microorganism, C-reactive protein, age, EuroSCORE II, total surgical time and the presence of postoperative complications were the major predictors of mortality and significantly impacted survival in up to a 10-year follow-up period.
活动性感染性心内膜炎与高发病率和死亡率相关。在高危情况下需进行手术治疗,应评估手术治疗中死亡率的主要决定因素。
确定长期随访中活动性感染性心内膜炎手术治疗的死亡率预测因素。
这项前瞻性观察性研究纳入了88例连续诊断为活动性感染性心内膜炎的患者,他们于2005年1月至2015年12月期间接受了手术。58例(65.9%)患者为男性,平均年龄为50.87±16.15岁。共有31例(35.2%)患者有风湿热病史;48例(54.5%)曾接受心脏手术并植入人工瓣膜;45例(93.8%)为生物人工瓣膜心内膜炎,3例(6.3%)为机械人工瓣膜心内膜炎;40例(45.5%)患者病变位于自身瓣膜。平均欧洲心脏手术风险评估系统(EuroSCORE)II评分为8.9±6.5%,主要手术指征为38例(43.2%)患者的难治性心力衰竭。共植入68个生物瓣膜(36个主动脉瓣,32个二尖瓣)和29个机械瓣膜(12个主动脉瓣,17个二尖瓣),并进行了3次二尖瓣成形术。共有25例(28.4%)患者接受了双瓣膜或三瓣膜手术。18例(20.5%)患者因脓肿进行了主动脉瓣环重建,6例(6.81%)患者进行了联合手术。平均手术时间为359±97.6分钟。
长达10年的随访期内总体生存率为79.5%。单因素分析中,主要的死亡率预测因素为血培养阳性(P=0.003)、典型微生物的存在(P=0.008),最常见的是草绿色链球菌(12例;25%);C反应蛋白(风险比[HR]1.034,95%置信区间[CI]1.000至1.070,P=0.04);肌酐清除率(HR 0.977,95%CI 0.962至0.993,P=0.005);手术时长:每延长5分钟死亡几率增加1.005倍(HR 1.005,95%CI 1.001至1.009,P=0.0307);年龄(HR 1.060,95%CI 1.026至1.096,P=0.001);以及EuroSCORE II(HR 1.089,95%CI 1.030至1.151,P=0.003)。
血培养阳性伴典型微生物、C反应蛋白、年龄、EuroSCORE II、总手术时间以及术后并发症的存在是死亡率的主要预测因素,在长达10年的随访期内对生存率有显著影响。